Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab Combined With Chemoradiotherapy in Locally Advanced Esophageal Cancer
NCT07530549Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in esophageal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT07530549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530549.